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to know
Samet, Jonathan M. 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
This presentation provides an overview of the current epidemiological 
evidence on the etiology of lung cancer. It presents a historical perspec-
tive, citing the identiﬁcation of multiple causes of lung cancer includ-
ing tobacco smoking and occupational and environmental agents. With 
this background, the presentation will then turn to critical questions 
that remain to be addressed and that are currently the focus of extensive 
research. 
The origins of the current pandemic of lung cancer lie in the rise of the 
modern cigarette industry at the start of the last century. The context 
for this presentation is set by more than half a century of epidemiologic 
research, carried out to identify the causes of lung cancer as a basis for 
preventing this highly fatal malignancy. The pandemic was ﬁrst noted 
through examination of mortality statistics and by astute clinicians who 
recognized that they were seeing increasing numbers of lung cancer 
cases. With regard to smoking and lung cancer, 1950 marks the start 
of a rising wave of epidemiological research on lung cancer. Even 
earlier, studies of miners had linked radon exposure to lung cancer, and 
several case-control studies on smoking and lung cancer were carried 
out in Nazi Germany. In 1950, the results of ﬁve case-control studies 
associating smoking with lung cancer were published, and by 1954, 
the “retrospective” ﬁndings of the case-control studies were conﬁrmed 
with the initial ﬁndings from Doll and Hill’s prospective cohort study 
of British physicians, the study of US Veterans, and the earliest of the 
cohort studies carried out by the American Cancer Society. Across 
the 1950s, ﬁndings of additional case-control and cohort studies were 
reported, leading to syntheses of the evidence in the early 1960s and 
the conclusion that smoking causes lung cancer.
For active smoking and lung cancer, the relationship of risk to the pat-
tern of smoking is well documented: risk increases with the number of 
cigarettes smoked; the duration of smoking; and it declines with increas-
ing duration of time since successful quitting. Smoking greatly increases 
the overall risk of lung cancer with current estimates showing about a 
20-fold higher risk, comparing current smokers to never smokers.
Over the four decades since the 1964 Surgeon General’s report, epide-
miological research on lung cancer has been conducted and ﬁndings 
reported with rising frequency. While cigarette smoking has always 
remained as a central theme, other causes have been evaluated and sub-
stantial research has been directed at other environmental factors and 
at genetic factors that might modify the risk of smoking. The causal 
agents identiﬁed include secondhand smoke (SHS) and a variety of oc-
cupational exposures, and urban air pollution generally. The search for 
modifying factors, particularly diet, has been less successful. In recent 
decades, researchers have increasingly addressed genetic determinants 
of lung cancer risk and much of the ongoing epidemiological research 
is based in the hybrid approach of “molecular epidemiology,” which 
joins laboratory and population research methods.
Just over two decades after the 1964 Surgeon General’s report, passive 
smoking, a widespread exposure, was found to be a cause of lung 
cancer. The ﬁrst major epidemiological studies on passive smoking 
and lung cancer were reported in 1981 and subsequently more than 
50 studies have been reported on exposure to secondhand smoke and 
lung cancer risk in never smokers. Passive smoking, i.e., inhaling SHS, 
causes lung cancer in never smokers, a conclusion reached in 1986 by 
the U.S. Surgeon General and reafﬁrmed in many subsequent reports, 
including, most recently, the 2006 Surgeon General’s report. This con-
clusion is supported by epidemiological studies, which show about a 
25% increased risk for never smokers married to smokers versus those 
married to never smokers, and by understanding the nature of tobacco 
smoke and the mechanisms by which it causes cancer.
Other air pollutants also contribute to the causation of lung cancer. 
Radon, long ago identiﬁed as an occupational carcinogen, is also a 
ubiquitous contaminant in indoor environments; it occurs naturally 
through the decay of uranium. It enters homes in the soil gas drawn 
into homes or in water, and in some circumstances, it may be released 
by building materials. There is a wide range of levels, with some homes 
having concentrations equivalent to those measured in uranium mines. 
Biological understanding implies that radon causes lung cancer at any 
level of exposure and that the exposure-response relationship is linear 
at typical indoor concentrations. For the United States, indoor radon is 
estimated to be the second leading cause of lung cancer. 
Indoor environments may also be contaminated by smoke from bio-
mass fuels and from cooking. Studies in several populations suggest 
that exposure to smoke indoors may increase lung cancer risk. Outdoor 
air is also contaminated by combustion-related carcinogens. While 
the risk has been difﬁcult to quantify, there is a general consensus that 
urban air pollution contributes to the causation of lung cancer. 
Occupational agents are also well established causes of lung cancer 
(Table 1), with associated risks that have been quite high in some 
worker groups. Evidence indicates that some occupational agents, e.g., 
radon, may interact synergistically with smoking, and thereby place 
workers who smoke at particularly high risk. For the population over-
all, occupational exposures have been estimated to cause a relatively 
small proportion of cases; estimates range from about 5 to 15% and 
vary by country and time period. 
At this time, the list of causal risk factors for lung cancer is lengthy 
(Table 1) and attributable risk estimates show that the occurrence of 
most cases of the disease can be explained. In countries where cigarette 
smoking has been prevalent for a half century or more, about 80 to 
90% of cases are attributable to this avoidable cause. Fortunately, some 
of these countries are now experiencing a downturn in lung cancer 
mortality rates, particularly among males, reﬂecting trends of increas-
ing quitting and declining initiation. 
In spite of the extensive epidemiological research directed at lung 
cancer, key issues remain under investigation and this presentation will 
provide syntheses of the evidence related to these issues:
• The changing trends of lung cancer histological types.
• The consequences of changing characteristics of cigarettes.
• Diet and gender as modiﬁers of the risk of smoking.
• The genetic determinants of lung cancer risk in smokers.
• The extent and causes of lung cancer in never smokers.
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Table 1. Causes of Lung Cancer
Smoking
Secondhand smoke exposure
Indoor radon
Occupational carcinogens, e.g., asbestos, 
arsenic, radon, chloromethyl ether
Outdoor air pollution
? Diet, other occupational factors
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Approximately 30% of all cancers in developed countries are caused 
by smoking and 80-90% of all lung cancers. Currently in the United 
States, approximately 50% of patients diagnosed with lung cancer are 
former smokers or never smokers with the remaining 50% being persis-
tent smokers. 76% of head and neck cancers are attributed to smoking 
and 51% continue to smoke during their therapy. These numbers are 
more difﬁcult to ascertain in more developing countries where the 
epidemic of smoking is in a different, earlier stage. However, there an 
estimated 1 billion smokers in the world today, and the majority are 
in developing countries. Therefore, the tobacco caused cancers, such 
as lung cancer will only continue to be an epidemic unless effective 
cessation programs are immediately instituted. Oncologists are acutely 
aware of the dangers of cigarette smoking and its relationship to car-
cinogenesis, however, they are not sufﬁciently active in helping their 
patients, already diagnosed with lung cancer, to stop them from persis-
tent smoking. In order to maximize clinical outcomes from therapy, it 
is important for the oncologists to work aggressively with their patients 
who are still smoking. It is not “too late”, and it is not too difﬁcult or 
too stressful for their patients to stop smoking. What is striking in the 
literature is the paucity of studies examining concurrent smoking status 
as related to treatment outcomes. It is unclear whether the oncologists 
are closely monitoring their patient’s smoking status or even consid-
ering it as a possible source of co-morbidity. Prospective studies are 
critical to examine the speciﬁc effect of smoking status on lung cancer 
chemotherapy or radiation therapy.
Current expert smoking cessation guidelines recommend two levels of 
intervention: in the primary care or oncologist’s ofﬁce or by a special-
ist in smoking cessation clinics or quitlines. The initial oncology ofﬁce 
visit is the ideal opportunity to explain the importance of cessation and 
to offer advice about stopping smoking.
The cornerstone of a smoking cessation strategy is the routine provision 
of the ‘”’5 A’s” with the use of pharmacotherapy. If there is a Quitline 
or other cessation services available, the ﬁrst 2 A’s with an R (refer to 
cessation services) are the recommend guideline.
The 5 A’s are:
ASK - about smoking status, how soon do they have their ﬁrst cigarette 
in the morning, number of cigarettes per day, how many times have 
they tried quit, what medication or method have they tried before and 
record it in the patient’s chart.
ADVISE - current smokers that if they quit, they will probably have 
an improved outcome from their oncologic therapy and a decrease 
potential for side effects. Personalize the reasons for stopping smoking 
and relate the reasons to their treatment. Have the patient set a quit date 
either for the current day, or within the next few days. Record in the 
patient’s chart their responses and intentions.
ASSESS - the current motivational status of the smoker to stop. Con-
sider a brief questionnaire that would identify the smoking status with 
the clinical intake form. Normally this step includes the assessment 
of whether the patient is ready to quit. However, for a patient with a 
diagnosis of lung cancer, this should be an abbreviated step. Use their 
diagnosis and need for treatment as the perfect teachable moment
ASSIST - smokers motivated to stop smoking by providing advice 
and support AND appropriate pharmacological therapy. Utilize the op-
portunity for referrals to quitlines that have been developed around the 
world. These quitlines provide cessation advice and support, are usu-
ally free and effective. The clinical ofﬁce simply identiﬁes the smoking 
status, reinforces the importance of stopping smoking and then refers 
the patient to the Quitline or cessation services. In some centers, such 
as Memorial Sloan-Kettering Hospital in New York City or the MD 
Anderson Cancer Center in Houston Texas, there are excellent referral 
programs that help patients to stop smoking within the center.
When assisting the patient to stop smoking, pharmacotherapy should be 
recommended to increase the efﬁcacy of the counseling therapy. Bupro-
pion SR 150 mg PO BID or varenicline xxx BID can be recommended 
for cessation therapy. At present, with the increasing information about 
the anti-apoptotic and proliferative effects of nicotine, NRT is not 
recommended for cessation therapy for a patient who has a diagnosis of 
cancer. When considering bupropion, there should be an assessment of 
a history of previous or current seizure or eating disorder, recent or cur-
rent use of MAOIs, severe hepatic cirrhosis, bipolar disorder, or drug 
interactions with theophylline, tricyclics, SSRIs, MAOIs, antipyschot-
ics, beta-blockers, class 1c antiarrhythmics, enzyme inducers, orphen-
adrine, cyclophosphamide. Of course, persistent smoking should also 
be considered with its concomitant drug interactions.
The patient should be urged to participate in the behavioural support 
programs that are offered with either Zyban, Chantix/Champix or Quit-
line/cessation services. These behavioral support programs may also 
be provided by their insurance companies in the USA. Other sources 
of support should be made available either through the oncology clinic, 
various other organizations, for example the American Cancer Society, 
or perhaps most easily through the state or national Quitline. Learn 
if you have one available! Behavioral support is critically important, 
especially for the lung cancer patient who not only just received a 
life-threatening diagnosis, but also must stop one of the most addictive 
substances in our society.
